Price
CHART BY
Frequently asked questions
What is Tarsus Pharms's market capitalization?
The market capitalization of Tarsus Pharms is $2.68B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Tarsus Pharms?
Tarsus Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.133. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Tarsus Pharms's stock?
Currently, 9 analysts cover Tarsus Pharms's stock, with a consensus target price of $94.00. Analyst ratings provide insights into the stock's expected performance.
What is Tarsus Pharms's revenue over the trailing twelve months?
Over the trailing twelve months, Tarsus Pharms reported a revenue of $535.08M.
What is the EBITDA for Tarsus Pharms?
Tarsus Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$49.08M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Tarsus Pharms?
Tarsus Pharms has a free cash flow of -$31.54M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Tarsus Pharms have, and what sector and industry does it belong to?
Tarsus Pharms employs approximately 370 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Tarsus Pharms's shares?
The free float of Tarsus Pharms is 40.37M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $2.68B
- EPS (TTM)
- -$1.133
- Free Float
- 40.37M
- Revenue (TTM)
- $535.08M
- EBITDA (TTM)
- -$49.08M
- Free Cashflow (TTM)
- -$31.54M
Pricing
- 52W span
- $38.53$85.00
Analyst Ratings
The price target is $94.00 and the stock is covered by 9 analysts.
Buy
9
Hold
0
Sell
0
Information
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
- Employees
- 370
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- TARS
Fundamentals & EOD data from FactSet